1. Home
  2. ESE vs COGT Comparison

ESE vs COGT Comparison

Compare ESE & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ESCO Technologies Inc.

ESE

ESCO Technologies Inc.

HOLD

Current Price

$267.50

Market Cap

5.2B

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$35.91

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESE
COGT
Founded
1990
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
6.0B
IPO Year
1994
2018

Fundamental Metrics

Financial Performance
Metric
ESE
COGT
Price
$267.50
$35.91
Analyst Decision
Strong Buy
Buy
Analyst Count
2
14
Target Price
$250.00
$34.77
AVG Volume (30 Days)
171.7K
1.6M
Earning Date
05-07-2026
05-22-2026
Dividend Yield
0.12%
N/A
EPS Growth
193.15
N/A
EPS
1.11
N/A
Revenue
$37,000,000.00
$7,871,000.00
Revenue This Year
$20.87
N/A
Revenue Next Year
$6.87
$1,180.55
P/E Ratio
$237.68
N/A
Revenue Growth
N/A
N/A
52 Week Low
$134.78
$3.72
52 Week High
$291.31
$43.73

Technical Indicators

Market Signals
Indicator
ESE
COGT
Relative Strength Index (RSI) 51.68 44.37
Support Level $198.85 $32.93
Resistance Level $290.82 $41.02
Average True Range (ATR) 9.54 1.80
MACD -3.43 -0.36
Stochastic Oscillator 22.39 32.48

Price Performance

Historical Comparison
ESE
COGT

About ESE ESCO Technologies Inc.

ESCO Technologies Inc sells engineered products and systems for utility, industrial, aerospace, and commercial applications. The firm operates in three segments: Aerospace & Defense (A&D), Utility Solutions Group (USG), and RF Test & Measurement (Test). The Aerospace and Defense segment designs and manufactures specialty filtration and naval products. The USG segment provides diagnostic testing solutions. The Test segment provides its customers with the ability to identify, measure, and contain magnetic, electromagnetic, and acoustic energy.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: